Anzeige
Mehr »
Login
Freitag, 22.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Diese Tech-Aktie könnte Ihr Portfolio revolutionieren – und die nächste große Sicherheitslücke schließen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

JCN Newswire-Archiv vom 31.10.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
31.10.Mazda Motor Corporation Mazda Launches Redesigned Corporate Website679- With enhanced convenience and newly established MAZDA MIRAI BAS for communicating Mazda's corporate activities to build a better future -HIROSHIMA, Japan, Oct 31, 2024 - (JCN Newswire) - Mazda Motor...
► Artikel lesen
31.10.Nippon Telegraph & Telephone Corp. (NTT): NTT and Toyota Motor Corporation agree to joint initiative in the field of mobility and AI/telecommunications with the aim of realizing a society with zero traffic accidents354Toyota City, Japan, Oct 31, 2024 - (JCN Newswire) - Today, Toyota Motor Corporation (hereafter, Toyota) and Nippon Telegraph and Telephone Corporation (hereafter, NTT) have agreed to a joint initiative...
► Artikel lesen
31.10.Mitsubishi Motors: All-New Triton Wins Golden Award at VMARK Vietnam Design Awards 2024351TOKYO, Oct 31, 2024 - (JCN Newswire) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that the all-new Triton has been selected as a golden award winner at the VMARK Vietnam...
► Artikel lesen
31.10.Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference314TOKYO and CAMBRIDGE, Mass., Oct 31, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI), an anti-amyloid beta...
► Artikel lesen
31.10.Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)296- Eisai Initiates Phase II Clinical Study on Sporadic Early Alzheimer's Disease -TOKYO, Oct 31, 2024 - (JCN Newswire) - Eisai Co. Ltd announced today that the latest findings on anti-MTBR (microtubule...
► Artikel lesen